Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies

INTRODUCTION: In the European Union (EU), the indication for the antifibrotic pirfenidone prior to April 2023 did not include patients with advanced idiopathic pulmonary fibrosis (IPF). This analysis compared the efficacy and safety of pirfenidone in advanced IPF versus non-advanced IPF. METHODS: Da...

Descripción completa

Detalles Bibliográficos
Autores principales: Behr, Jürgen, Nathan, Steven D., Costabel, Ulrich, Albera, Carlo, Wuyts, Wim A., Glassberg, Marilyn K., Haller, Harold, Alvaro, Giuseppe, Gilberg, Frank, Samara, Katerina, Lancaster, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427557/
https://www.ncbi.nlm.nih.gov/pubmed/37391667
http://dx.doi.org/10.1007/s12325-023-02565-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427557/
https://www.ncbi.nlm.nih.gov/pubmed/37391667
http://dx.doi.org/10.1007/s12325-023-02565-3

Ejemplares similares